Loading clinical trials...
Loading clinical trials...
FOLFOXIRI in Combination With GM-CSF and IL-2 (FOLFOXIGIL) Versus FOLFOXIRI as First-line Treatment for Patients With Metastatic Colorectal Cancer: a Phase II Trial by the FNF Team.
Conditions
Interventions
Irinotecan
Oxaliplatin
+4 more
Locations
1
China
Rongbo Lin
Fuzhou, Fujian, China
Start Date
July 20, 2017
Primary Completion Date
July 20, 2019
Completion Date
July 20, 2020
Last Updated
March 27, 2018
NCT04657068
NCT06625775
NCT06607458
NCT06820463
NCT07361003
NCT06792695
Lead Sponsor
Fujian Cancer Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions